Pharmacognosy ODM
ODM Potency Study & Origin Standardization
Quantifying phytochemical variance across geo-origins and harvest seasons to secure the highest assay purity.
From single active phytomolecules to multi-phase non-clinical evaluation, our audited facilities provide turn-key Contract Development and Manufacturing services.
Quantifying phytochemical variance across geo-origins and harvest seasons to secure the highest assay purity.
Full GLP-compliant in vivo validation testing for systemic toxicity, bio-distribution, and potency benchmarks.
Validation of chromatographic fingerprints, impurity separation, and reference standards for global DMF filings.
High-throughput isolation and bio-fractionation across alkaloids, polyphenols, terpenoids, and saponins.
Target-specific receptor binding, enzymatic inhibition assays, and cellular cytotoxicity evaluations.
ICH-GCP registered clinical trials covering pharmacokinetics, tolerability, dose-escalation, and multicenter claims.
End-to-end evaluation of wildcrafted and cultivated botanical materials ensuring consistent active fractions.
Pilot-to-commercial isolation engineering with solvent recovery, crystallization, and flash column chromatography.
An authoritative analysis of botanical chemistry isolation, impurity fingerprinting, and global contract manufacturing compliance.
In the contemporary pharmaceutical, cosmeceutical, and advanced nutraceutical landscape, the demand for high-purity botanical active ingredients has superseded empirical phytotherapy. Today's global innovators are turning to specialised ODM purity manufacturers and suppliers capable of delivering active pharmaceutical ingredients (APIs), standardized phytochemical isolates (ranging from 90% to >99.5% pure fractions), and target-oriented formulations backed by verifiable spectroscopic data.
Operating out of Changsha, Hunan—the historic cradle of Chinese herbal medicine science and modern high-tech extraction—MedGence (Yineng Pharma) serves as a premier natural medicine Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Backed by more than 14 years of rigorous R&D experience, over 300 research scientists, and an empirical database covering hundreds of thousands of research batches, MedGence provides the definitive bridge between raw botanical biodiversity and commercially viable, cGMP-grade purity.
Elimination of isomeric impurities, solvent traces, heavy metals, and pesticide residues below stringent ICH Q3A/Q3B limits through preparative HPLC and multi-stage resin fractionation.
Seamless operational progression from botanical compound screening, extraction chemistry optimization, and bio-fractionation to pilot-plant engineering and commercial production.
Entrusted custom contract synthesis under ironclad bilateral Non-Disclosure Agreements (NDAs). Proprietary purification methodologies and master formulation records remain customer-exclusive.
Quantified leadership in botanical active ingredient screening, analytical standardization, and commercial ODM scale-up.
Why the confluence of botanical agronomy, advanced industrial crystallization, and integrated CDMO supply lines creates an unmatched sourcing advantage in China.
China possesses over 11,000 medicinal plant species and represents the global hub for geo-authentic ("Daodi") botanical cultivations. A core bottleneck in botanical purity manufacturing is raw biomass variability: seasonal rainfalls, altitude, soil mineralogy, and harvest timing can cause a 400% fluctuation in target active concentrations.
Our Changsha engineering center leverages multi-seasonal origin evaluation maps, enabling procurement engineers to lock down raw botanicals during peak phytochemical expression windows. This downstream feedstock consistency minimizes solvent consumption, maximizes extraction yield, and dramatically reduces batch-to-batch chromatographic divergence.
Chinese purity suppliers have made monumental technological transitions from rudimentary solvent baths to closed-loop automated extraction systems. Integrating macroporous adsorption resin columns, simulated moving beds (SMB), continuous countercurrent extraction, and preparative-scale SFC (supercritical fluid chromatography) allows high throughput production of isolated molecules (such as Huperzine A, Resveratrol, Ginsenosides, Artemisinin derivatives, and Epimedium icariin) at commercial volumes unattainable elsewhere.
The global high-purity natural compound industry is undergoing three transformative macro transitions:
MedGence's integrated CRO-CDMO framework directly addresses these paradigms, ensuring every batch delivered is supported by rigorous analytical documentation and international regulatory filing data.
| Analytical Metric | Standard Commercial Extract | MedGence High-Purity ODM Benchmark | Validation / Verification Protocol |
|---|---|---|---|
| Assay Purity (Target Active) | 10.0% – 50.0% Crude Mix | 95.0% – 99.8% Chromatographic Purity | HPLC-DAD / GC-FID / Q-TOF LC/MS |
| Unknown Single Impurity | > 2.0% - Unidentified | ≤ 0.10% (Individually Quantified) | ICH Q3A Guideline Validation |
| Residual Solvents | Class 2/3 traces < 5000 ppm | Class 1: Non-Detectable; Class 3 < 500 ppm | Headspace GC-MS (USP <467>) |
| Heavy Metals (Pb, Cd, As, Hg) | < 10.0 ppm - 20.0 ppm cumulative | ≤ 0.5 ppm Individual Heavy Metals | ICP-MS Inductively Coupled Plasma |
| Microbiological Bioburden | < 10,000 CFU/g | ≤ 100 CFU/g (Irradiation-Free / Sterile Options) | USP <61> / <62> Microbial Enumeration |
| Batch Reproducibility (RSD) | ± 8.0% - 15.0% Variance | RSD ≤ 1.5% Across 10+ Commercial Batches | HPTLC & HPLC Chromatographic Overlay |
Bridging molecular-level phytochemical engineering with global commercialization pipelines across diverse regulated industries.
Purified phyto-compounds engineered as primary Active Pharmaceutical Ingredients or novel synthesis precursors. Supported by complete Drug Master Files (DMF), stability data under ICH Q1A-E guidelines, and validated stress-testing (photostability, acid/base hydrolysis, thermal degradation).
Clinically substantiated natural formulations engineered for enhanced bioavailability, sustained-release profiles, and synergistic bio-efficacy. Customized into finished dosage forms: softgels, bilayer tablets, chewable gummies, microencapsulated beadlets, and stabilized soluble powders.
Ultra-pure, non-sensitizing plant actives with zero odor or coloration artifacts. Targeted for transdermal penetration, anti-inflammatory, tyrosinase inhibition, and cellular senolytic mechanisms. Validated via in vitro human keratinocyte (HaCaT) and reconstructed skin assays.
Multinational pharma and nutraceutical corporations navigating cross-border botanical ingredient supply face complex regulatory and operational audits. MedGence’s contract infrastructure is purpose-engineered to satisfy top-tier vendor qualification metrics:
Complete electronic records aligned with FDA 21 CFR Part 11 and cGMP computer validation protocols. Unalterable spectroscopic archives from raw accession to release.
Dual-facility manufacturing capacity ensures uncompromised delivery timelines and volume scalability from multi-kilo clinical batches to multi-metric-ton commercial campaigns.
Experienced technical teams delivering comprehensive regulatory documentation for US FDA (NDI, GRAS), European EFSA Novel Food, and China NMPA registrations.
Access our complete spectrum of preclinical screening, process characterization, and turnkey contract production capabilities.
Phenotypic and target-guided bio-fractionation across broad medicinal herb matrices.
Metabolic disease, anti-inflammatory, and neuroprotective animal models validating therapeutic response.
Comprehensive chemical identification, peak similarity indexes, and stability tracking assays.
ELISA, western blot, qPCR, and flow cytometry assays evaluating signaling pathways and cytotoxicity.
GCP-compliant human trials substantiating structure-function claims and NDA therapeutic filings.
Translating traditional synergistic recipes into optimized, scientifically verified oral dosage vehicles.
Commercial production supplied as crystalline powders, standardized fluids, and spray-dried granules.
End-to-end manufacturing for tablets, softgels, hard capsules, sachets, and functional liquids under cleanroom specs.
Direct technical and commercial clarifications for enterprise R&D heads, regulatory directors, and sourcing managers.
Connect directly with our analytical chemistry and process engineering team. Receive technical feasibility scoping, chromatographic target evaluation, and pilot pricing within 48 hours.